Liu Meng-Yun, Yang Zhen-Yu, Dai Wen-Kui, Huang Jian-Qiong, Li Yin-Hu, Zhang Juan, Qiu Chuang-Zhao, Wei Chun, Zhou Qian, Sun Xin, Feng Xin, Li Dong-Fang, Wang He-Ping, Zheng Yue-Jie
Meng-Yun Liu, Jian-Qiong Huang, He-Ping Wang, Yue-Jie Zheng, Department of Respiratory, Shenzhen Children's Hospital, Shenzhen 518026, China.
World J Gastroenterol. 2017 Mar 28;23(12):2149-2158. doi: 10.3748/wjg.v23.i12.2149.
To determine whether oral administration of CGMCC313-2 ( CGMCC313-2) inhibits allergen-induced airway inflammation and food allergies in a mouse model.
Ovalbumin (OVA)-induced allergic asthma and β-lactoglobulin-induced food allergy mouse models were used in this study. Following oral administration of CGMCC313-2 during or after allergen sensitization, histopathologic changes in the lung and intestine were evaluated by hematoxylin and eosin (HE) staining. In the allergic asthma mouse model, we evaluated the proportion of lung-infiltrating inflammatory cells. OVA-specific IgE and IgG1 levels in serum and cytokine levels in bronchoalveolar lavage fluid (BALF) were also assessed. In the food allergy mouse model, the levels of total IgE and cytokines in serum were measured.
Oral administration of CGMCC313-2 during or after allergen sensitization suppressed allergic inflammation in lung and intestinal tissues, while the proportion of infiltrating inflammatory cells was significantly decreased in the BALF of allergic asthma mice. Moreover, CGMCC313-2 decreased the serum levels of total IgE in food allergy mice, and reductions in IgE and IgG1 were also observed in OVA-induced allergic asthma mice. The expression of interleukin-4 (IL-4) and IL-13 in both serum and BALF was suppressed following the administration of CGMCC313-2, while an effect on serum IL-10 levels was not observed.
CGMCC313-2 inhibits the secretion of allergen-induced IgE, IL-4 and IL-13, and attenuates allergic inflammation.
在小鼠模型中确定口服中国普通微生物菌种保藏管理中心313 - 2（CGMCC313 - 2）是否能抑制变应原诱导的气道炎症和食物过敏。
本研究采用卵清蛋白（OVA）诱导的过敏性哮喘和β - 乳球蛋白诱导的食物过敏小鼠模型。在变应原致敏期间或之后口服CGMCC313 - 2，通过苏木精和伊红（HE）染色评估肺和肠道的组织病理学变化。在过敏性哮喘小鼠模型中，我们评估了肺浸润炎症细胞的比例。还评估了血清中OVA特异性IgE和IgG1水平以及支气管肺泡灌洗液（BALF）中的细胞因子水平。在食物过敏小鼠模型中，测量了血清中总IgE和细胞因子的水平。
在变应原致敏期间或之后口服CGMCC313 - 2可抑制肺和肠道组织中的过敏性炎症，而过敏性哮喘小鼠的BALF中浸润炎症细胞的比例显著降低。此外，CGMCC313 - 2降低了食物过敏小鼠血清中总IgE水平，在OVA诱导的过敏性哮喘小鼠中也观察到IgE和IgG1的降低。给予CGMCC313 - 2后，血清和BALF中白细胞介素 - 4（IL - 4）和IL - 13的表达均受到抑制，而未观察到对血清IL - 10水平的影响。
CGMCC313 - 2抑制变应原诱导的IgE、IL - 4和IL - 13的分泌，并减轻过敏性炎症。
